Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sumitomo Pharma America, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject or legal guardian provides written informed consent. For eligible subjects under age 18, verbal assent is also required.
The subject has completed the extension phase of a prior lurasidone clinical study. Eligible subjects may enroll into this continuation study directly (or within 10 days) after completing the extension phase of a prior lurasidone clinical study. Subjects that have completed an extension study prior to the initiation of this protocol at the study site, may participate in this study up to 3 months after completion of the extension phase of the prior lurasidone study.
The subject is judged by the Investigator to be suitable for participation in a clinical study involving open-label lurasidone treatment and is able to comply with the protocol.
The subject, in the Investigator's judgment, may benefit from continued treatment with lurasidone
You may not be if
The subject is considered by the Investigator, to be at imminent risk for homicidal or suicidal behavior.
The subject resides in a country where lurasidone has been approved for any indication.
The subject is currently enrolled in any other investigational study.
The subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
